WO2013038195A3 - Compositions de nanoparticules pharmaceutiques - Google Patents

Compositions de nanoparticules pharmaceutiques Download PDF

Info

Publication number
WO2013038195A3
WO2013038195A3 PCT/GB2012/052272 GB2012052272W WO2013038195A3 WO 2013038195 A3 WO2013038195 A3 WO 2013038195A3 GB 2012052272 W GB2012052272 W GB 2012052272W WO 2013038195 A3 WO2013038195 A3 WO 2013038195A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticle compositions
pharmaceutical nanoparticle
pharmaceutical
ocular
nanoparticles
Prior art date
Application number
PCT/GB2012/052272
Other languages
English (en)
Other versions
WO2013038195A2 (fr
Inventor
Francesca CRAWFORD
Philip Gunning
David HERMANS
Deepak Thassu
Original Assignee
Altacor Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altacor Limited filed Critical Altacor Limited
Priority to CA2845673A priority Critical patent/CA2845673A1/fr
Priority to EP12762374.2A priority patent/EP2755659A2/fr
Priority to CN201280044324.4A priority patent/CN103930115A/zh
Publication of WO2013038195A2 publication Critical patent/WO2013038195A2/fr
Publication of WO2013038195A3 publication Critical patent/WO2013038195A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation de nanoparticules d'antagonistes glucocorticoïdes pour le traitement de pathologies oculaires et non-oculaires, ainsi que des compositions les contenant et leurs procédés de préparation.
PCT/GB2012/052272 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques WO2013038195A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2845673A CA2845673A1 (fr) 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques
EP12762374.2A EP2755659A2 (fr) 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques
CN201280044324.4A CN103930115A (zh) 2011-09-13 2012-09-13 药物纳米粒组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534248P 2011-09-13 2011-09-13
US61/534,248 2011-09-13

Publications (2)

Publication Number Publication Date
WO2013038195A2 WO2013038195A2 (fr) 2013-03-21
WO2013038195A3 true WO2013038195A3 (fr) 2013-07-04

Family

ID=46889367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/052272 WO2013038195A2 (fr) 2011-09-13 2012-09-13 Compositions de nanoparticules pharmaceutiques

Country Status (4)

Country Link
EP (1) EP2755659A2 (fr)
CN (1) CN103930115A (fr)
CA (1) CA2845673A1 (fr)
WO (1) WO2013038195A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017001863A (es) 2014-08-13 2017-07-17 Univ Johns Hopkins Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.
WO2019118979A1 (fr) 2017-12-15 2019-06-20 Georgetown University Procédés de traitement de lésions résiduelles d'anomalies vasculaires
WO2023033900A1 (fr) * 2021-09-06 2023-03-09 Slayback Pharma Llc Compositions pharmaceutiques de mifépristone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084637A2 (fr) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Nouveaux procedes et nouvelle composition d'administration de macromolecules par voie orale
WO2007083145A1 (fr) * 2006-01-19 2007-07-26 Summit (Cambridge) Limited Traitement des états pathologiques oculaires et des effets secondaires systémiques des glucocorticoïdes
US20100105643A1 (en) * 2008-10-27 2010-04-29 Soll David B Ophthalmic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090798A (en) 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
EP1916976A2 (fr) 2005-08-25 2008-05-07 pSivida Inc Regulation d'une elevation de pression intra-oculaire induite
US20110268775A1 (en) 2009-01-06 2011-11-03 Pharmanova, Inc. Nanoparticle pharmaceutical formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084637A2 (fr) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Nouveaux procedes et nouvelle composition d'administration de macromolecules par voie orale
WO2007083145A1 (fr) * 2006-01-19 2007-07-26 Summit (Cambridge) Limited Traitement des états pathologiques oculaires et des effets secondaires systémiques des glucocorticoïdes
US20100105643A1 (en) * 2008-10-27 2010-04-29 Soll David B Ophthalmic composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI V H K ET AL: "Ocular drug delivery of progesterone using nanoparticles", JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS, BASINGSTOKE, GB, vol. 3, no. 3, 1 January 1986 (1986-01-01), pages 213 - 218, XP009166491, ISSN: 0265-2048 *
W HE ET AL: "Improved bioavailability of orally administered mifepristone from PLGA nanoparticles", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 334, no. 1-2, 4 April 2007 (2007-04-04), pages 173 - 178, XP055049805, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2006.10.025 *

Also Published As

Publication number Publication date
EP2755659A2 (fr) 2014-07-23
WO2013038195A2 (fr) 2013-03-21
CA2845673A1 (fr) 2013-03-21
CN103930115A (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX350589B (es) Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
WO2014031610A8 (fr) Procédés permettant de traiter ou d'empêcher l'asthme par administration d'un antagoniste du récepteur à l'interleukine 4 (il-4r)
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
WO2012177844A3 (fr) Composés d'imidazopyridinyle-aminopyridine substitués
MX366899B (es) Nuevos compuestos.
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
WO2012106393A3 (fr) Withanolide isolé à partir de physalis longifolia et ses analogues et procédés d'utilisation
WO2013022991A3 (fr) Méthodes et compositions associées à p62 pour le traitement et la prophylaxie du cancer
WO2012080926A3 (fr) Anticorps anti-notch1
PH12014501078A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11�-17-21-triol-3,20-dione derivatives
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
WO2014066799A3 (fr) Modulateurs du récepteur des androgènes androgéno-résistant
WO2011129936A3 (fr) Compositions et procédés pour la prévention et le traitement du cancer
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
WO2016011049A3 (fr) Compositions et procédés pour le traitement de maladies à l'aide de composés distribués sous forme de nanoparticules
WO2014068586A3 (fr) Compositions orales solides de tolvaptan
WO2012040331A3 (fr) Nanoparticules multicouches
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
WO2013016205A3 (fr) Compositions et méthodes pour réduire l'incidence de troubles digestifs chez des équidés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12762374

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2845673

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012762374

Country of ref document: EP